{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/KURA/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-22T11:59:17.173Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":3594,"canonical_name":"Kura Oncology, Inc.","cik":"0001422143","uei":null,"lei":null,"duns":null,"ticker":"KURA"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":26,"clinical":4},"count":30,"timeline":[{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — Kura Oncology, Inc. — 2026-06-22","url_slug":"/sec/cik-0001422143/4/0001193125-26-277780","accession_number":"0001193125-26-277780","importance":30},{"ts":"2026-06-18","kind":"sec.form144","reporter":"MOLLIE VANESSA LEONI","title":"Officer","shares":84929,"usd_value":812771,"security_title":"Common","approx_sale_date":"2026-06-18","accession_number":"0001950047-26-006310","importance":40.162554106},{"ts":"2026-06-18","kind":"sec.insider.s","reporter":"Leoni Mollie","title":"Chief Medical Officer","shares":84929,"price_per_share":9.8233,"usd_value":834283,"security_title":"Common Stock","importance":35.8342830457},{"ts":"2026-06-18","kind":"sec.filing","form_type":"144","title":"144 — Kura Oncology, Inc. — 2026-06-18","url_slug":"/sec/cik-0001422143/144/0001950047-26-006310","accession_number":"0001950047-26-006310","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Kura Oncology, Inc. — 2026-06-04","url_slug":"/sec/cik-0001422143/8-k/0001193125-26-257368","accession_number":"0001193125-26-257368","importance":35},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — Kura Oncology, Inc. — 2026-06-04","url_slug":"/sec/cik-0001422143/4/0001193125-26-257900","accession_number":"0001193125-26-257900","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — Kura Oncology, Inc. — 2026-06-04","url_slug":"/sec/cik-0001422143/4/0001193125-26-257902","accession_number":"0001193125-26-257902","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — Kura Oncology, Inc. — 2026-06-04","url_slug":"/sec/cik-0001422143/4/0001193125-26-257903","accession_number":"0001193125-26-257903","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"S-8","title":"S-8 — Kura Oncology, Inc. — 2026-06-04","url_slug":"/sec/cik-0001422143/s-8/0001193125-26-257777","accession_number":"0001193125-26-257777","importance":30},{"ts":"2026-05-21","kind":"sec.form144","reporter":"BRIAN POWL","title":"Officer","shares":10000,"usd_value":103400,"security_title":"Common","approx_sale_date":"2026-05-21","accession_number":"0001950047-26-004907","importance":40.02068},{"ts":"2026-05-21","kind":"sec.filing","form_type":"144","title":"144 — Kura Oncology, Inc. — 2026-05-21","url_slug":"/sec/cik-0001422143/144/0001950047-26-004907","accession_number":"0001950047-26-004907","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Kura Oncology, Inc. — 2026-05-20","url_slug":"/sec/cik-0001422143/4/0001193125-26-232546","accession_number":"0001193125-26-232546","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Kura Oncology, Inc. — 2026-05-20","url_slug":"/sec/cik-0001422143/4/0001193125-26-232547","accession_number":"0001193125-26-232547","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Kura Oncology, Inc. — 2026-05-20","url_slug":"/sec/cik-0001422143/4/0001193125-26-232548","accession_number":"0001193125-26-232548","importance":30},{"ts":"2026-05-19","kind":"sec.form144","reporter":"KATHLEEN FORD","title":"Officer","shares":2257,"usd_value":20764,"security_title":"Common","approx_sale_date":"2026-05-19","accession_number":"0001950047-26-004793","importance":40.00415288},{"ts":"2026-05-19","kind":"sec.form144","reporter":"BRIAN POWL","title":"Officer","shares":339,"usd_value":3119,"security_title":"Common","approx_sale_date":"2026-05-19","accession_number":"0001950047-26-004789","importance":40.00062376},{"ts":"2026-05-19","kind":"sec.insider.s","reporter":"FORD KATHLEEN","title":"Chief Operating Officer","shares":2257,"price_per_share":9.0752,"usd_value":20483,"security_title":"Common Stock","importance":35.0204827264},{"ts":"2026-05-19","kind":"sec.insider.s","reporter":"Powl Brian T.","title":"Chief Commercial Officer","shares":339,"price_per_share":9.21,"usd_value":3122,"security_title":"Common Stock","importance":35.00312219},{"ts":"2026-05-19","kind":"sec.filing","form_type":"144","title":"144 — Kura Oncology, Inc. — 2026-05-19","url_slug":"/sec/cik-0001422143/144/0001950047-26-004789","accession_number":"0001950047-26-004789","importance":30},{"ts":"2026-05-19","kind":"sec.filing","form_type":"144","title":"144 — Kura Oncology, Inc. — 2026-05-19","url_slug":"/sec/cik-0001422143/144/0001950047-26-004793","accession_number":"0001950047-26-004793","importance":30},{"ts":"2026-05-18","kind":"sec.form144","reporter":"TERESA BAIR","title":"Officer","shares":2256,"usd_value":20800,"security_title":"Common","approx_sale_date":"2026-05-18","accession_number":"0001950047-26-004689","importance":40.004160064},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Bair Teresa Brophy","title":"Chief Legal Officer","shares":2256,"price_per_share":9.3795,"usd_value":21160,"security_title":"Common Stock","importance":35.021160152},{"ts":"2026-05-18","kind":"sec.filing","form_type":"144","title":"144 — Kura Oncology, Inc. — 2026-05-18","url_slug":"/sec/cik-0001422143/144/0001950047-26-004689","accession_number":"0001950047-26-004689","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Kura Oncology, Inc. — 2026-05-15","url_slug":"/sec/cik-0001422143/schedule-13g-a/0001172661-26-002164","accession_number":"0001172661-26-002164","importance":30},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"Kura Oncology, Inc.","title":"First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia","security_title":"PHASE1,PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04067336","excerpt":"[\"Advanced Malignant Neoplasm\",\"Acute Myeloid Leukemia\",\"Mixed Lineage Leukemia\",\"Mixed Lineage Acute Leukemia\",\"Acute Leukemia of Ambiguous Lineage\",\"Mixed Phenotype Acute Leukemia\",\"Acute Lymphoblastic Leukemia\"]","importance":45},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"Kura Oncology, Inc.","title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07007312","excerpt":"[\"Acute Myeloid Leukemia (AML)\"]","importance":60},{"ts":"2026-05-12","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Kura Oncology, Inc. — 2026-05-12","url_slug":"/sec/cik-0001422143/10-q/0001193125-26-219481","accession_number":"0001193125-26-219481","importance":45},{"ts":"2026-05-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Kura Oncology, Inc. — 2026-05-12","url_slug":"/sec/cik-0001422143/8-k/0001193125-26-219422","accession_number":"0001193125-26-219422","importance":35},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Kura Oncology, Inc.","title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06026410","excerpt":"[\"Solid Tumors With HRAS Alterations\",\"Non Small Cell Lung Cancer (NSCLC)\",\"Colorectal Cancer (CRC)\",\"Pancreatic Ductal Adenocarcinoma (PDAC)\",\"Clear Cell Renal Cell Carcinoma (ccRCC)\",\"Renal Cell Carcinoma (Kidney Cancer)\",\"Non Clear Cell Renal Cell Carcinoma (nccRCC)\"]","importance":30},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Kura Oncology, Inc.","title":"Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06001788","excerpt":"[\"AML\",\"AML With Mutated NPM1\",\"Hematologic Malignancy\",\"KMT2Ar\",\"NPM1 Mutation\",\"MLL Rearrangement\",\"Leukemia\",\"Acute Myeloid Leukemia\",\"Leukemia, Myeloid\",\"Leukemia, Myeloid, Acute\",\"Acute Leukemia\",\"Neoplasms by Histologic Type\"]","importance":30}]}